Capital Research Global Investors Decreases Holdings in Insulet Corporation $PODD

Capital Research Global Investors lessened its stake in shares of Insulet Corporation (NASDAQ:PODD) by 3.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 4,408,972 shares of the medical instruments supplier’s stock after selling 140,097 shares during the quarter. Capital Research Global Investors owned approximately 0.06% of Insulet worth $1,253,224,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in PODD. Larson Financial Group LLC increased its holdings in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares during the last quarter. Elyxium Wealth LLC purchased a new stake in Insulet during the fourth quarter worth about $28,000. Fideuram Asset Management Ireland dac purchased a new stake in Insulet during the fourth quarter worth about $41,000. Measured Wealth Private Client Group LLC purchased a new stake in Insulet during the third quarter worth about $49,000. Finally, Osterweis Capital Management Inc. purchased a new stake in Insulet during the second quarter worth about $51,000.

Insulet Price Performance

PODD opened at $153.22 on Friday. The firm has a 50-day moving average price of $175.73 and a 200-day moving average price of $238.90. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. Insulet Corporation has a twelve month low of $140.63 and a twelve month high of $354.88. The company has a market capitalization of $10.61 billion, a price-to-earnings ratio of 35.63, a PEG ratio of 1.21 and a beta of 1.13.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. During the same period last year, the business earned $1.02 earnings per share. Insulet’s revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities analysts expect that Insulet Corporation will post 6.46 EPS for the current year.

Insider Activity at Insulet

In other news, Director Timothy C. Stonesifer acquired 2,790 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the transaction, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.36% of the company’s stock.

Analyst Ratings Changes

PODD has been the subject of several recent research reports. Stifel Nicolaus reduced their target price on shares of Insulet from $350.00 to $250.00 in a research note on Thursday, May 7th. Piper Sandler reduced their target price on shares of Insulet from $360.00 to $210.00 in a research note on Wednesday, May 6th. Leerink Partners reduced their target price on shares of Insulet from $360.00 to $247.00 in a research note on Thursday, May 7th. Evercore reduced their target price on shares of Insulet from $240.00 to $200.00 in a research note on Thursday, May 7th. Finally, Jefferies Financial Group reduced their target price on shares of Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. Twenty-one analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and an average target price of $252.04.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.